Contrast dye study in ICU patients: what happens to kidney markers?
NCT ID NCT02881710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 50 intensive care patients to see how a contrast dye used in CT scans changes two kidney injury markers (TIMP-2 and IGFBP7) in urine. The goal was to understand if the dye causes a measurable increase in these markers. It was a small, observational study without a comparison group, so it helps gather knowledge rather than proving a treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- contrast dye (iodinated contrast agent)
- What this could lead to
- If successful, this could help doctors better understand how contrast dye affects kidneys in critically ill patients, potentially leading to safer scanning practices.
- What could go wrong
- This is a small, early observational study with no control group, so results may not apply broadly. It only measures markers, not actual kidney outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMERGENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nantes
Nantes, 44093, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- French ICUs under the microscope: how safe are they really?
- New study aims to boost First-Attempt intubation success in the field
- New tool could spot tough pneumonia early
- Massive study aims to make emergency breathing tubes safer
- Game on: digital distraction eases Kids' pain during stitches
- Emergency room Follow-Up: do patients listen?